The financing and organization of medical care for patients with end-stage renal disease in Sweden
- PMID: 17657602
- DOI: 10.1007/s10754-007-9014-y
The financing and organization of medical care for patients with end-stage renal disease in Sweden
Abstract
The total health care expenditure as a percentage of the gross domestic product in Sweden is 9.2%, and health care is funded by global budgets almost entirely through general taxation. The prevalence rate of end-stage renal disease (ESRD) in Sweden is 756 per million. Fifty-two percent of ESRD patients have a functioning transplant. Almost all ESRD treatment facilities are public. Compared with other Dialysis Outcomes and Practice Patterns Study (DOPPS) countries, the salaries for both nephrologists and professional dialysis unit staff are low. Sweden's high cost per ESRD patient, relative to other DOPPS countries, may be a result of expensive and frequent hospitalizations and aggressive anemia treatment strategies.
Similar articles
-
The organization and financing of end-stage renal disease in Spain.Int J Health Care Finance Econ. 2007 Dec;7(4):253-67. doi: 10.1007/s10754-007-9021-z. Int J Health Care Finance Econ. 2007. PMID: 17602295
-
The organization and financing of dialysis and kidney transplantation services in New Zealand.Int J Health Care Finance Econ. 2007 Dec;7(4):233-52. doi: 10.1007/s10754-007-9023-x. Int J Health Care Finance Econ. 2007. PMID: 17638073
-
International Study of Health Care Organization and Financing of renal services in England and Wales.Int J Health Care Finance Econ. 2007 Dec;7(4):283-99. doi: 10.1007/s10754-007-9015-x. Int J Health Care Finance Econ. 2007. PMID: 17653861
-
International Study of Health Care Organization and Financing for end-stage renal disease in France.Int J Health Care Finance Econ. 2007 Sep;7(2-3):171-83. doi: 10.1007/s10754-007-9025-8. Int J Health Care Finance Econ. 2007. PMID: 17680359 Review.
-
End-stage renal disease and economic incentives: the International Study of Health Care Organization and Financing (ISHCOF).Int J Health Care Finance Econ. 2007 Sep;7(2-3):73-111. doi: 10.1007/s10754-007-9024-9. Int J Health Care Finance Econ. 2007. PMID: 17653860 Review.
Cited by
-
International study of health care organization and financing: development of renal replacement therapy in Germany.Int J Health Care Finance Econ. 2007 Sep;7(2-3):185-200. doi: 10.1007/s10754-007-9020-0. Int J Health Care Finance Econ. 2007. PMID: 17701342
-
Mortality in chronic kidney disease and renal replacement therapy: a population-based cohort study.BMJ Open. 2014 Feb 18;4(2):e004251. doi: 10.1136/bmjopen-2013-004251. BMJ Open. 2014. PMID: 24549162 Free PMC article.
-
Compensated living kidney donation: a plea for pragmatism.Health Care Anal. 2010 Mar;18(1):85-101. doi: 10.1007/s10728-008-0110-z. Epub 2009 Jan 29. Health Care Anal. 2010. PMID: 19184442
-
The increase in renal replacement therapy (RRT) incidence has come to an end in Sweden-analysis of variations by region over the period 1991-2010.Clin Kidney J. 2013 Jun;6(3):352-7. doi: 10.1093/ckj/sft032. Clin Kidney J. 2013. PMID: 26064505 Free PMC article.
-
Quantifying the Treatment Effect of Kidney Transplantation Relative to Dialysis on Survival Time: New Results Based on Propensity Score Weighting and Longitudinal Observational Data from Sweden.Int J Environ Res Public Health. 2020 Oct 7;17(19):7318. doi: 10.3390/ijerph17197318. Int J Environ Res Public Health. 2020. PMID: 33036407 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical